Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.
Acta Pharm Sin B
; 11(11): 3417-3432, 2021 Nov.
Article
em En
| MEDLINE
| ID: mdl-34900527
AD, Alzheimer disease; ALARM NMR, a La assay to detect reactive molecules by nuclear magnetic resonance; Biochemical experiment; CADD, computer-aided drug design technology; CoA, coenzyme A; EGFR, epidermal growth factor receptor; Fair trial strategy; GSH, glutathione; HER2, human epidermal growth factor receptor 2; HTS, high-throughput screening; In silico filtering; LC−MS, liquid chromatography−mass spectrometry; MTDLs, multitarget-directed ligands; Multitarget-directed ligands; PAINS suspects; PAINS, pan-assay interference compounds; QSAR, quantitative structureactivity relationship; ROS, radicals and oxygen reactive species
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article